Open access
Open access
Powered by Google Translator Translator

Randomized Trials

RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer

25 Apr, 2023 | 14:24h | UTC

Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence

 

Commentary on Twitter

 


RCT | Oral fluvoxamine plus inhaled budesonide reduced hospitalizations in high-risk patients with early-onset COVID-19

24 Apr, 2023 | 13:51h | UTC

Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial – Annals of Internal Medicine

Commentary: Combination of fluvoxamine and inhaled budesonide reduces severe COVID-19 in high-risk outpatients – News Medical

 

Commentary on Twitter

 


RCT | Higher dose corticosteroids increase mortality in hypoxic COVID-19 patients on simple oxygen

24 Apr, 2023 | 13:55h | UTC

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Editorial: Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia? – The Lancet

Commentary: Higher-dose corticosteroids tied to 60% more deaths in low-oxygen COVID patients – CIDRAP

 

Commentary on Twitter (thread – click for more)

 


RCT | No difference in atrial fibrillation recurrence with early vs. delayed AF ablation at 12 months

24 Apr, 2023 | 13:49h | UTC

Impact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences – European Heart Journal (link to abstract – $ for full-text. Free PDF may be available here)

 

Commentary on Twitter

 


RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer

24 Apr, 2023 | 13:41h | UTC

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


RCT | Stereotactic radiosurgery vs. conventional radiotherapy for localized vertebral metastases of the spine

24 Apr, 2023 | 13:37h | UTC

Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Audio interview: Radiosurgery of Spine Metastasis—NRG/RTOG 0631 RCT Final Results – JAMA

 

Commentary on Twitter

 


RCT | Piperacillin-tazobactam better than cefoxitin in antimicrobial prophylaxis for open pancreatoduodenectomy

21 Apr, 2023 | 13:08h | UTC

Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Informing a Rational Approach to Antimicrobial Prophylaxis in Open Pancreatoduodenectomy – JAMA (free for a limited period)

 

Commentary on Twitter

 


Review | The importance of using placebo controls in nonpharmacological randomized trials

21 Apr, 2023 | 13:02h | UTC

The importance of using placebo controls in nonpharmacological randomised trials – Pain

 


RCT | Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata

21 Apr, 2023 | 13:00h | UTC

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Progress in search for alopecia areata treatment for adolescents  – Yale News

 

Commentary on Twitter

 


RCT | Prophylactic tranexamic acid in cesarean delivery did not significantly reduce maternal death or transfusion risk

19 Apr, 2023 | 13:22h | UTC

Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Tranexamic acid does not appear to prevent maternal hemorrhage after cesarean delivery – National Institutes of Health

 

Commentary on Twitter

 


RCT | Blood donor’s sex does not impact transfusion recipients’ survival

19 Apr, 2023 | 13:20h | UTC

Effect of Donor Sex on Recipient Mortality in Transfusion – New England Journal of Medicine (link to abstract – $ for full-text)

News release: Sex of blood donor has no effect on recipient survival – Ottawa Hospital

 

Commentary on Twitter

 


RCT | Small benefit from pembrolizumab + gemcitabine/cisplatin vs. gemcitabine/cisplatin alone in advanced biliary tract cancer

19 Apr, 2023 | 13:10h | UTC

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers – American Association for Cancer Research

 

Commentary on Twitter

 


RCT | Operative hysteroscopy vs. vacuum aspiration for incomplete spontaneous abortion

18 Apr, 2023 | 13:04h | UTC

Operative Hysteroscopy vs Vacuum Aspiration for Incomplete Spontaneous Abortion: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | MRI–guided vs CT–guided stereotactic body radiotherapy for prostate cancer

18 Apr, 2023 | 12:52h | UTC

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial – JAMA Oncology

News Release: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California – Los Angeles Health Sciences

 


RCT | Heterogeneity in blood pressure response to 4 antihypertensive drugs

17 Apr, 2023 | 13:14h | UTC

Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial – JAMA (free for a limited period)

News Release: Personalized blood pressure treatment more effective – Uppsala University

Commentary: Hypertension: Personalized Treatment May Reduce Need for Higher Doses and Multiple Medications – MedicalResearch.com

 


Phase 2 RCT | High-dose VE303 reduces recurrent Clostridioides difficile infection rates

17 Apr, 2023 | 13:12h | UTC

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual Abstract

 


RCT | Exercise and protein intervention may improve resilience and reduce frailty in seniors

17 Apr, 2023 | 13:04h | UTC

Building resilience and reversing frailty: a randomised controlled trial of a primary care intervention for older adults – Age and Ageing

 


Phase 2 RCT | Dersimelagon in erythropoietic protoporphyrias

17 Apr, 2023 | 13:05h | UTC

Dersimelagon in Erythropoietic Protoporphyrias – News England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Zolbetuximab plus mFOLFOX6 in CLDN18.2+ HER2- advanced gastric or gastro-oesophageal junction adenocarcinoma

17 Apr, 2023 | 13:00h | UTC

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet – PR Newswire

 


RCT | Safety of Fezolinetant for vasomotor symptoms associated with menopause

17 Apr, 2023 | 12:54h | UTC

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial – Obstetrics and Gynecology

Related:

RCT | Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause

RCT | Efficacy of Fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause

 


The earlier the better: an RCT of treatment timing effects for toddlers on the autism spectrum

17 Apr, 2023 | 12:52h | UTC

The earlier the better: An RCT of treatment timing effects for toddlers on the autism spectrum – Autism

News Release: Researchers find earlier intervention leads to greater improvements in young children on the autism spectrum – Children’s Hospital of Philadelphia

 


RCT | 10-year results show low-dose tamoxifen reduces noninvasive breast cancer recurrence

17 Apr, 2023 | 12:50h | UTC

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Low-Dose Tamoxifen to Prevent Recurrence in Patients With Breast Noninvasive Neoplasia: 10-Year Follow-up of TAM-01 Trial – The ASCO Post

 


RCT | Hydroxyurea for secondary stroke prevention in children with sickle cell anemia

17 Apr, 2023 | 12:48h | UTC

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial – Blood

 


RCT | Doxycycline postexposure prophylaxis effective in preventing gonorrhea, chlamydia, and syphilis in MSM

12 Apr, 2023 | 13:30h | UTC

Summary: In this open-label, randomized study involving 501 men who have sex with men (MSM) and transgender women, researchers investigated the effectiveness of postexposure doxycycline in preventing bacterial sexually transmitted infections (STIs), specifically gonorrhea, chlamydia, and syphilis. Participants with a previous STI in the past year, either taking preexposure prophylaxis (PrEP) against HIV or living with HIV, were randomly assigned to receive 200 mg of doxycycline within 72 hours after condomless sex or standard care without doxycycline. STI testing was performed quarterly, with the primary end point being the incidence of at least one STI per follow-up quarter.

Results demonstrated a significant reduction in STI incidence in both the PrEP and persons living with HIV cohorts who received doxycycline.  Overall, the combined incidence of these three STIs was lower by two thirds with doxycycline postexposure prophylaxis compared to standard care. The study also reported five grade 3 adverse events but no serious adverse events attributed to doxycycline. This finding supports the use of doxycycline postexposure prophylaxis among MSM with recent bacterial STIs.

Article: Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Doxycycline after sex found to reduce STI incidence in gay men, transgender women – CIDRAP

 

Commentary on Twitter

 


RCT | Effects of focal vs. extended irreversible electroporation ablation of localized prostate cancer

12 Apr, 2023 | 13:05h | UTC

Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)

Commentary: Focal vs Extended Irreversible Electroporation in Ablation of Localized Low- or Intermediate-Risk Prostate Cancer – The ASCO Post

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.